Ulcerative Colitis Flare
Conditions
Keywords
Immune cells, Inflamed + non-inflamed biopsies + correlated blood samples, Flow cytometry, IHC, Single cell RNA sequencing, Immunoprofiling
Brief summary
Immune-mediated diseases are extremely diverse - patients with the same diagnosis may see the disease progress in very different ways, and respond differently to treatments. This is because the course of the disease is influenced by multiple factors, including the patient's genes, immune system, environment, and the microbes living in their gut. Furthermore, all of these factors interact with and impact on one another. As a result, it is very hard to predict how the disease will develop in a specific patient, and which treatments will be effective. Hence, mechanistic understanding of this heterogeneity and biomarkers predictive for disease control and therapy response over time are important prerequisites of a future precision medicine in IMIDs. ImmUniverse has been formed as a European transdisciplinary consortium to tackle these unmet needs and to understand the role of the crosstalk between tissue microenvironment and immune cells in disease progression and response to therapy of ulcerative colitis (UC) and atopic dermatitis (AD). The consortium will combine analysis of tissue-derived signatures with circulating signatures detectable in liquid biopsies, employing state-of-the-art profiling technologies to provide new validated diagnostics in IMID that are expected to improve patient management, lead to increased patient well-being and will significantly reduce the socioeconomic burden of these diseases. This study, being Immuniverse work package 5 (WP5), will verify the disease pathway -and mechanism signatures identified in the multi omic discovery WP2 in immune cells in affected tissue and peripheral blood. WP5 aims to further substantiate our understanding of the immune-mediated intestinal disease ulcerative colitis (UC). It will use liquid biopsies (peripheral blood) and affected UC gut inflamed and non-inflamed biopsies to generate transcriptome, proteome, DNA-methylome and miRNA signatures of immune cell subsets and analyse the association between immune cells circulating in peripheral blood and the microenvironment of affected colonic tissue. Also this WP aims to develop a protocol to analyse and sort living immune cells from cryopreserved tissue. Ultimately, the project's findings should contribute to a better, more precise diagnosis for patients; and better information on how severe the disease is likely to be for each individual patient and how it will progress over time. Finally, the project will make it easier for doctors and patients to monitor how well a treatment is working in the future.
Interventions
None listed
Sponsors
Radboud University Medical Center
Study design
Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Inclusion criteria
* Diagnosis of Ulcerative Colitis * Age ≥ 18 years * Present in the hospital for a regular outpatient visit * Willing and able to comply with the study related procedures * Provide signed informed consent
Exclusion criteria
* Age ≤ 18 years * Unable to give informed consent * Unable or unwilling to comply with study-related procedures * Crohn's Disease or IBD undiagnosed
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Comparing immune cells in blood, inflamed and uninflamed colonic biopsies by means of flow cytometry | Through study completion, an average of 1.5 years | Assessed by differences in Mean Fluorescent Intensity in whole blood sampels vs. inflamed and uninflamed biopsies |
| Comparing gene expression profiles in blood, inflamed and uninflamed colonic biopsies | Through study completion, an average of 1.5 years | Assessment of mean expression of genes in blood vs. inflamed and uninflamed biopsies by means of single cell RNA sequencing |
| Localizing immune cells of interest of inflamed and uninflamed biopsies | Through study completion, an average of 1.5 years | By using immunohistochemistry: quantified by cells per field |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| For 40 patients: montreal classification | Through study completion, an average of 1.5 years | 1. E1: ulcerative proctitis 2. E2: left-sided UC (distal to splenic flexure) 3. E3: Entensive UC (pancolitis) |
| For 40 patients: SCCAI-score | Through study completion, an average of 1.5 years | Based on 6 variables: 1. Bowel frequency (day) 2. Bowel frequency (night) 3. Urgency of defecation 4. Blood in stool 5. General well-being 6. Extracolonic features |
| For 40 patients: Mayo score (based on physician rating of endoscopic disease activity) | Through study completion, an average of 1.5 years | 0: normal or inactive disease 1: mild disease (erythema, decreased vascular pattern, mild friability) 2. Moderate disease (marked erythema, absent vascular pattern, friability, erosions) 3. Severe disease (spontaneous bleeding, ulcerations) |
| For 40 patients: Medication history and current medication | Through study completion, an average of 1.5 years | anti-TNF, Vedolizumab, Janus kinase inhibitors, thiopurine, methotrexate, aminosalicylates, corticosteroids (grams of medication/day) |
| For 40 patients: height | Through study completion, an average of 1.5 years | Height in centimeter, combined with weight to get to BMI (kg/m\^2) |
| For 40 patients: Albumin | Through study completion, an average of 1.5 years | g/L |
| For 40 patients: infections in stool | Through study completion, an average of 1.5 years | yes/no |
| Blood parameters | Through study completion, an average of 1.5 years | WBC count (\*10\^9/L), RBC count (\*10\^12/L), PLT (\*10\^9/L), Lymphocytes (\*10\^9/L), Monocytes (\*10\^9/L), Neutrophils (\*10\^9/L), Eosinophils (\*10\^9/L), Basiphils (\*10\^9/L) |
| For 40 patients: Feacel calprotectin | Through study completion, an average of 1.5 years | mg/kg feces |
| For 40 patients: weight | Through study completion, an average of 1.5 years | Weight in kilograms, combined with height to get to BMI (kg/m\^2) |
| For 40 patients: smoking status | Through study completion, an average of 1.5 years | 1. Current/active smoker 2. Previous smoker 3. Never smoked 4. Not described |
Countries
Netherlands
Contacts
Primary ContactHans Koenen
Backup ContactLaurien Waaijer
Outcome results
None listed